p95HER2.CAR-TECH2Me (Vall D'Hebron Institute Of Oncology)

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug Namep95HER2.CAR-TECH2Me (Vall D'Hebron Institute Of Oncology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived
Mechanisms of ActionT lymphocyte replacements
TargetsUpdating
Therapy Area/IndicationsMetastatic breast cancerEndometrial NeoplasmsStomach Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVall D'Hebron Institute Of Oncology
China Registration ClassN/A

Develop Information

Active CompaniesVall D'Hebron Institute Of Oncology
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerEndometrial NeoplasmsStomach Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A